Concepedia

Author

Paul Fields

Adaptive Biotechnologies (United States)ORCID

Also Known As

Brien J.D, Fields P, Fields, Paul, P A Fields, P. A. Fields, P. Fields, P.A. Fields, Paul A Fields, Paul A. Fields, Paul A. Fields (449352)

121

Publications

4.4K

Citations

28

H-Index

57

Concepts

All Affiliations

Adaptive Biotechnologies (United States)University of PennsylvaniaUniversity of WashingtonChildren's Hospital of PhiladelphiaHuman Gene Therapy Research Institute
PF

About

Paul Fields is an author at Adaptive Biotechnologies (United States) specializing in medicine, immunology, and autoimmunity.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

11

2.3K

2

Cell Biology

4

4

326

3

Health Sciences

1

1

48

4

Allergy

1

1

128

5

Cellular Physiology

1

1

76

Paul Fields

×

35

Publications

4.1K

Citations

26

H-Index

YearCitations

Braveheart, a Long Noncoding RNA Required for Cardiovascular Lineage Commitment

Carla Klattenhoff, Johanna C. Scheuermann, Lauren E. Surface,

Cell

2013

916

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector

Roland W. Herzog, Edmund Y. Yang, Linda B. Couto,

Nature Medicine

1999

562

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Galit Alter, Jingyou Yu, Jinyan Liu,

Nature

2021

342

Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels

Thomas M. Snyder, Rachel M. Gittelman, Mark Klinger,

2020

233

Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

Devalingam Mahalingam, Grey Wilkinson, Kevin H. Eng,

Clinical Cancer Research

2019

171

Dynamics of genome reorganization during human cardiogenesis reveal an RBM20-dependent splicing factory

Alessandro Bertero, Paul Fields, Vijay Ramani,

Nature Communications

2019

170

Lack of Germline Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vector in Males

Valder R. Arruda, Paul Fields, Ross Milner,

Molecular Therapy

2001

152

Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene Therapy

Roland W. Herzog, Paul Fields, Valder R. Arruda,

Human Gene Therapy

2002

144

Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX

Paul Fields, Dariusz Kowalczyk, Valder R. Arruda,

Molecular Therapy

2000

128

Risk and Prevention of Anti-factor IX Formation in AAV-Mediated Gene Transfer in the Context of a Large Deletion of F9

Paul Fields, Valder R. Arruda, Elina Armstrong,

Molecular Therapy

2001

125

Page 1